Active Ingredient History
Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired resistance/intolerance. It’s used for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms. Dasatinib is also undergoing preclinical evaluation for its potential as a therapy against multiple myeloma. Bristol-Myers Squibb has a composition-of-matter patent covering this research approach that will expire in 2020. Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (approved 2006)
Adenocarcinoma (Phase 2)
Aging (Phase 2)
Alzheimer Disease (Phase 2)
Anemia (Phase 1)
Bile Duct Neoplasms (Phase 2)
Blast Crisis (Phase 2)
Brain Diseases (Phase 1)
Brain Neoplasms (Phase 2)
Brain Stem Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Central Nervous System Diseases (Phase 1)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 2)
Chordoma (Phase 2)
Chronic Disease (Phase 2)
Cognitive Dysfunction (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 2)
Dasatinib (Phase 4)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Drugs, Investigational (Phase 3)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Frailty (Phase 2)
Fusion Proteins, bcr-abl (Phase 4)
Gallbladder Neoplasms (Phase 1)
Gastrointestinal Stromal Tumors (Phase 2)
Giant Cell Tumor of Bone (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 2)
Hemangiopericytoma (Phase 2)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 3)
Hodgkin Disease (Phase 1/Phase 2)
Hypereosinophilic Syndrome (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 1)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2/Phase 3)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 1/Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Myeloid (Phase 1/Phase 2)
Leukemia, Myeloid, Accelerated Phase (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 4)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Mastocytosis (Phase 2)
Mastocytosis, Systemic (Phase 2)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Mycosis Fungoides (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 2/Phase 3)
Neoplasms ()
Neuroblastoma (Phase 2)
Neurofibrosarcoma (Phase 2)
Oocytes (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pinealoma (Phase 2)
Polycythemia Vera (Phase 2)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 3)
Renal Insufficiency, Chronic (Phase 2)
Rhabdomyosarcoma (Phase 2)
Rhabdomyosarcoma, Alveolar (Phase 1/Phase 2)
Rhabdomyosarcoma, Embryonal (Phase 1/Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Sarcoma, Ewing (Phase 2)
Scleroderma, Systemic (Phase 2)
Sezary Syndrome (Phase 1)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Substance Withdrawal Syndrome (Phase 2)
Testicular Neoplasms (Phase 3)
Thyroid Neoplasms (Phase 2)
Tongue Neoplasms (Phase 2)
Translocation, Genetic (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
